Baxter Launches HEMOPATCH, an Innovative Sealing Hemostat, in
European Union

October 23, 2013 09:00 AM Eastern Daylight Time

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the launch of
HEMOPATCH Sealing Hemostat, a novel collagen-based hemostatic device,
following CE mark approval in Europe. HEMOPATCH is a resorbable
hemostatic device used for surgical procedures when control of bleeding
by pressure, ligature or conventional procedures is either ineffective
or impractical. The development of HEMOPATCH combined Baxter’s expertise
in collagen, internal coagulation processes, and PEG (polyethylene
glycol) technology platforms.

''HEMOPATCH is a valuable addition to the tools in the surgical suite,
as it provides fast hemostasis and strong tissue adherence. Surgeons
will appreciate that the product works quickly and effectively, does not
require preparation time, and can be used in a range of surgical
settings,'' said Frank Ulrich, M.D., head of surgical oncology at Goethe
University in Frankfurt, Germany.

HEMOPATCH is a soft, thin and flexible collagen pad that is designed to
allow surgeons control during application to gain hemostasis and firm
adherence of the hemostatic pad to the bleeding tissue surface. In
preclinical tests, HEMOPATCH achieved fast and effective hemostasis,
reaching 97.5 percent success by fully controlling bleeding at two
minutes.

The pad consists of a specifically-formulated porous collagen matrix,
coated on one side with a thin protein bonding layer (known as NHS-PEG).
This gives the pad a dual-method mechanism of action, in which two
components interact to achieve hemostasis by sealing off the bleeding
surface and initiating the body’s own clotting mechanisms. Significant
preclinical testing was conducted to confirm its hemostatic performance,
biocompatibility, and safety profile.

''HEMOPATCH is a significant innovation in the field of surgical
hemostasis and is a valuable enhancement to the portfolio of biosurgical
products offered by Baxter,'' said Russell Holscher, vice president of
research and development in Baxter’s BioSurgery business. ''Importantly,
the robust development process, including evaluation of more than 400
prototypes with feedback from more than 200 surgeons, exemplifies the
company’s commitment to customer-centric innovation. This hemostat will
offer surgeons a valuable new tool. We plan to support the registration
and launch of HEMOPATCH in additional countries in the coming years.''

About HEMOPATCH

HEMOPATCH Sealing Hemostat is intended as a hemostatic device for
surgical procedures when control of bleeding by pressure, ligature, or
conventional procedures is either ineffective or impractical.

Important Risk Information

HEMOPATCH Sealing Hemostat is not intended to be used in pulsatile,
severe bleedings. The use of HEMOPATCH Sealing Hemostat is not
recommended in the presence of an active infection. When used in,
around, or in proximity to foramina in bone, areas of bony confine, the
spinal cord, and/or the optic nerve and chiasm, care should be exercised
to avoid overpacking (collagens do expand upon absorption of liquid, and
may create the potential of nerve damage). HEMOPATCH Sealing Hemostat is
not intended as a substitute for meticulous surgical technique and the
proper application of ligatures or other conventional procedures for
hemostasis.

Do not compress HEMOPATCH Sealing Hemostat into blood vessels or use
intravascularly. The device must not be used in patients with known
hypersensitivity to bovine proteins or brilliant blue (FD&C #1, blue
dye).

About Baxter in BioSurgery

Baxter’s BioSurgery franchise began with the acquisition of Immuno
International AG, in the 1990s and the first launch of a hemostatic
device in the United States in 1998. Today, Baxter’s BioSurgery
portfolio consists of a range of biological and synthetic products and
delivery devices used for hemostasis, tissue sealing, adhesion
reduction, hard tissue regeneration, as well as soft tissue repair and
microsurgery products. These products advance surgical care for surgeons
and their patients in more than 60 countries across the world.

About Baxter International Inc.

Baxter International Inc., through its subsidiaries, develops,
manufactures and markets products that save and sustain the lives of
people with hemophilia, immune disorders, cancer, infectious diseases,
kidney disease, trauma and other chronic and acute medical conditions.
As a global, diversified healthcare company, Baxter applies a unique
combination of expertise in medical devices, pharmaceuticals and
biotechnology to create products that advance patient care worldwide.

This release includes forward-looking statements concerning
HEMOPATCH, including expectations with regard to anticipated regulatory
filings. The statements are based on assumptions about many important
factors, including the following, which could cause actual results to
differ materially from those in the forward-looking statements:
satisfaction of regulatory approval and other requirements; actions of
regulatory bodies and other governmental authorities; product quality or
patient safety issues; changes in law and regulations; and other risks
identified in Baxter's most recent filing on Form 10-K and other SEC
filings, all of which are available on Baxter's website. Baxter does not
undertake to update its forward-looking statements.